Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Status:
Recruiting
Trial end date:
2028-03-02
Target enrollment:
Participant gender:
Summary
The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic
esophageal squamous cell carcinomas remains unknown. One of our objectives is to evaluate
whether the neo-adjuvant immunochemotherapy Toripalimab (JS001) with cisplatin and paclitaxel
followed by right thoracic approach esophagectomy with total 2-field lymph node dissection
improves the overall survival of thoracic esophageal cancer patients versus neo-adjuvant
chemotherapy.